The World Journal of Oncology, published by ELMER PRESS INC, is a vibrant platform for disseminating groundbreaking research and advancements in the field of oncology. With its ISSN 1920-4531 and E-ISSN 1920-454X, this journal is dedicated to publishing high-quality studies that enhance our understanding of cancer and its treatment. The journal is recognized for its significant contributions, evidenced by its Q2 classification in both Cancer Research and Oncology categories in 2023, and accolades such as a Scopus rank of #126/404 in Medicine _ Oncology. Catering to the needs of researchers, professionals, and students, the World Journal of Oncology offers an essential resource for the latest scientific insights and clinical practices, ensuring the global oncology community remains informed and engaged. The journal operates under a selective publication model, maintaining rigor in peer review while facilitating knowledge sharing across converged years from 2014 to 2016 and 2020 to 2024, further establishing its importance in the ongoing fight against cancer.

Bone Reports is a premier, peer-reviewed journal published by Elsevier that has been committed to advancing the field of orthopedics, sports medicine, and endocrinology since its inception as an open-access journal in 2015. With an ISSN of 2352-1872, this esteemed publication seeks to disseminate high-quality research that spans a diverse array of topics related to bone health, metabolic diseases, and musculoskeletal disorders. The journal boasts an impressive impact factor, contributing significantly to its recognition, with a Q2 ranking in Orthopedics and Sports Medicine and a Q3 ranking in Endocrinology, Diabetes, and Metabolism as of 2023. This open-access model enhances accessibility and engagement, allowing researchers, professionals, and students alike to stay at the forefront of developments in these critical areas. With an emphasis on rigorous methodology and innovative findings, Bone Reports is poised to become a vital resource for anyone interested in the latest advances in bone research and clinical applications.

JOURNAL OF BONE AND MINERAL METABOLISM, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing the field of bone and mineral research since its establishment in 1988. With ISSN 0914-8779 and E-ISSN 1435-5604, this esteemed journal offers a platform for high-quality research that intersects Endocrinology, Diabetes and Metabolism, Orthopedics and Sports Medicine, and related disciplines. Recognized for its rigorous standards, it holds a commendable Q2 ranking in multiple categories, reflecting its broad influence and relevance in contemporary medical research. Researchers and practitioners alike benefit from its evidence-based articles and insights, which contribute significantly to our understanding of metabolic bone diseases and mineral homeostasis. Although not an open-access journal, it still provides essential information and advancements crucial for professionals and scholars dedicated to improving clinical outcomes and enhancing patient care in these vital areas. To learn more, please explore the journal's archives and latest publications.

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

Journal of Osteoporosis is a leading open-access journal dedicated to the investigation and dissemination of research in the field of osteoporosis and related bone disorders. Published by HINDAWI LTD, the journal has been fostering academic discourse since 2010, ensuring that critical findings are accessible to researchers, clinicians, and policy-makers alike. With an ISSN of 2090-8059 and an E-ISSN of 2042-0064, it serves as a significant platform for advancing knowledge in Endocrinology, Diabetes, and Metabolism, currently holding Q4 and Q3 categorizations in respective quartiles as of 2023. The journal, which publishes annually and is based in the United States, plays a crucial role in documenting the evolving understanding of bone health, contributing to improved clinical practices and patient outcomes. As it converges insights from diverse fields, it is an essential resource for researchers aiming to impact the future of osteoporosis management and treatment.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Translational Lung Cancer Research is a leading journal dedicated to advancing the field of oncology, particularly focusing on groundbreaking discoveries in lung cancer treatment and management. Published by AME Publishing Company, this journal boasts an impressive Q1 classification in the 2023 Oncology category, reflecting its significant contribution to the scientific community, with an outstanding Scopus rank of #92 out of 404 in Medicine _ Oncology, placing it in the 77th percentile. With its commitment to open access, the journal fosters international collaboration and accessibility, making cutting-edge research available to a wide audience. The scope of Translational Lung Cancer Research encompasses clinical trials, experimental studies, and translational research that bridge the gap between laboratory findings and clinical applications. Researchers, professionals, and students seeking to keep abreast of the latest developments in lung cancer research will find invaluable insights within its pages. For further information, please contact at FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG.

Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

Bone Research is a premier open-access journal published by SpringerNature, dedicated to advancing the understanding of bone biology and its related disciplines. Established in 2013 and based in the United Kingdom, this journal has quickly ascended to the forefront of scientific inquiry, evidenced by its esteemed Q1 rankings in 2023 across multiple categories including Endocrinology, Diabetes and Metabolism, Histology, and Physiology. With a commendable impact reflected in its Scopus ranks—positioned #2 in Histology, #9 in Endocrinology, and #8 in Physiology—Bone Research serves as a vital platform for researchers, healthcare professionals, and students alike to share and access cutting-edge findings. Since adopting an open-access model in 2014, the journal has empowered an expansive audience by facilitating immediate availability of high-quality research. This aligns with its commitment to foster innovation and collaboration within the fields it encompasses. As it converges its efforts from 2013 to 2024, Bone Research remains a critical resource for those looking to deepen their investigation into bone health and diseases, ensuring its place as a leader in promoting scientific excellence.